Key result
Hospitalization for decompensated heart failure in 2016-2017 was associated with a lower 2-year all-cause mortality rate (33%) compared to 2010-2011 (44%), although rehospitalizations increased.
Why the study?
Most previous studies of hospitalized HF exacerbation were conducted in large clinical centers, leaving detailed analyses of patients hospitalized in district general hospitals lacking.
Does hospitalization in a more recent era (2016-2017) compared to an older era (2010-2011) improve 2-year mortality in patients with decompensated heart failure in a district general hospital?
Cohort (n=394)
No
Does hospitalization in a more recent era (2016-2017) compared to an older era (2010-2011) improve 2-year mortality in patients with decompensated heart failure in a district general hospital?
While 2-year mortality for decompensated HF in a district hospital improved from 2010 to 2017, rehospitalization rates increased and device therapy remained underutilized.
Answers are grounded in this paper and cite their sources.
Declining mortality with rising rehospitalizations in decompensated HF; hypothesis-generating and should not yet change practice.
BACKGROUND: Patients hospitalized for heart failure (HF) exacerbation tend to have a poor prognosis. Most previous studies were performed in large clinical centers and detailed analyses of patients with HF hospitalized in district general hospitals are lacking. AIMS: The aim of this study was to assess the outcomes of patients admitted with HF exacerbation to a district general hospital. METHODS: We retrospectively enrolled patients hospitalized for HF exacerbation in the years 2010 to 2011 (191 patients) and 2016 to 2017 (203 patients). The primary and secondary endpoints were all‑cause mortality and rehospitalization due to HF exacerbation, respectively, within a 2‑year follow‑up. RESULTS: Compared with patients hospitalized from 2010 to 2011, those hospitalized from 2016 to 2017 had more favorable clinical parameters and more appropriate pharmacological treatment; however, the rate of implantable cardioverter‑defibrillator and resynchronization device use remained low. The overall mortality decreased from 44% between 2010 and 2011 to 33% between 2016 and 2017 (P = 0.03), but the number of rehospitalizations increased from 26% to 41%, respectively (P <0.001). Male sex, low systolic blood pressure, symptoms of right HF, and renal dysfunction were independent risk factors for the primary endpoint. Symptoms of right HF, renal dysfunction, left ventricular ejection fraction below 24%, and low systolic blood pressure independently predicted the secondary endpoint. CONCLUSIONS: The prognosis of patients hospitalized for decompensated HF in a regional district hospital was poor. Despite some improvement in pharmacological treatment, which probably led to reduced all‑‑cause mortality, there was a low rate of implantable electronic device use and a high rate of rehospitalizations due to HF exacerbation, which needs further elucidation.
No takes yet. Share an insight, caveat, or question.
Dobrowolska et al. (2021) conducted a cohort in Decompensated heart failure (n=394). Hospitalization in 2016-2017 vs. Hospitalization in 2010-2011 was evaluated on All-cause mortality within 2 years (p=0.03). Hospitalization for decompensated heart failure in 2016-2017 was associated with a lower 2-year all-cause mortality rate (33%) compared to 2010-2011 (44%), although rehospitalizations increased.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: